Moderna, Inc. MRNA
Composite 33/100; the shares have moved about 262% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 1/100 — a strong mark against it.
Momentum ranks 65/100 — a moderate point in its favour. Balance-sheet strength ranks 65/100 — a moderate point in its favour.
Growth ranks 1/100 — a strong mark against it. Quality ranks 8/100 — a strong mark against it. Valuation ranks 30/100 — a moderate mark against it.
What the company does Moderna, Inc. (MRNA) develops messenger RNA-based medicines across respiratory, latent, enteric, public health, bacterial, oncology, and rare disease segments. Its pipeline includes vaccines for COVID-19, RSV, influenza, and HIV, alongside therapeutics like cancer antigen therapies. The company collaborates with Merck, Vertex, and the Gates Foundation to advance mRNA innovation.
Key financials Moderna’s profitability metrics remain weak: ROE -39%, ROA -13.3%, and ROCE -36.4%. Gross margin is -66.0%, with operating and net margins at -557.9% and -141.4%, respectively. Revenue declined -39.2%, while debt/equity stands at 0.19 with a current ratio of 2.29.
Stock health Momentum is strong: 3-month +238.01%, 6-month +209.59%, and 12-month +540.39%. RSI(14) is 67.50, suggesting overbought conditions. Strength pillar score is 66.2, while quality scores (7.8) and growth (1.8) are weak.
Price vs fair value The stock trades at a **PREMIUM of 32.20%** versus the analyst mean target of 104.53. - Jim Cramer highlights upside potential despite heavy short interest (CNBC). - IBD flags MRNA as a "Stock of the Day," citing momentum (IBD). - Sideravia’s valuation percentile (27.4/100) and EV/EBITDA (4.64) reinforce rich pricing.
Looking forward Forward P/E of 23.04 suggests high expectations for future earnings growth. However, weak fundamentals and rich valuation may limit upside unless pipeline progress accelerates.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.